According to SOLAR-1 (NCT02437318) and BYLieve (NCT03056755, cohort A) trials, breast cancer patients carrying PIK3CA mutations who received any CDK4/6 inhibitor and fulvestrant treatment followed by alpelisib had a better prognosis [33]. Here, PIK3CA is linked to breast carcinoma.